Understanding Adrenocortical Carcinoma

Adrenocortical carcinoma (ACC) is a rare and aggressive cancer arising from the adrenal cortex, the outer layer of the adrenal glands. These glands, located atop each kidney, produce essential hormones such as cortisol, aldosterone, and androgens. ACC can disrupt hormone balance and cause a variety of symptoms, often leading to delayed diagnosis. This article provides a comprehensive overview of ACC symptoms, diagnostic approaches, and the role of genetic testing in management.

Anatomy and Function of the Adrenal Cortex

The adrenal glands are small, triangular-shaped organs that sit on top of each kidney. Each gland consists of two distinct parts: the outer adrenal cortex and the inner adrenal medulla. The cortex produces three main types of hormones:

• Glucocorticoids (e.g., cortisol): Regulate metabolism, immune response, and stress.
• Mineralocorticoids (e.g., aldosterone): Control blood pressure and electrolyte balance.
• Androgens: Precursors to sex hormones, influencing secondary sexual characteristics.

When malignant cells develop in the adrenal cortex, they can overproduce these hormones, leading to distinct clinical syndromes. Alternatively, the tumor may grow silently, causing symptoms only through mass effect.

Clinical Presentation: Hormonal and Mass Effects

Symptoms of ACC depend on whether the tumor is functional (hormone-secreting) or non-functional. Functional tumors often present with signs of hormone excess, while non-functional tumors may remain asymptomatic until they grow large enough to cause local compression or metastasis.

Hormonal Syndromes

The most common hormonal syndromes associated with ACC include:

• Cushing's Syndrome: Due to cortisol excess, presenting with weight gain, central obesity, moon facies, purple striae, and proximal muscle weakness.
• Virilization: Due to androgen excess, especially in women, causing hirsutism, deepening of voice, and menstrual irregularities.
• Feminization: Rarely, estrogen excess in men leads to gynecomastia and loss of libido.
• Hyperaldosteronism: Aldosterone excess causes hypertension and hypokalemia, though less common in ACC.

Mass Effect Symptoms

As the tumor enlarges, it may cause:

• Abdominal or flank pain
• Palpable mass
• Early satiety or nausea
• Weight loss (in advanced disease)

Prognostic Impact of Early Diagnosis

Early detection of ACC is critical because the tumor is often aggressive and can metastasize quickly. When confined to the adrenal gland (Stage I or II), surgical resection offers a 5-year survival rate of 50–80%. In contrast, advanced disease (Stage IV) has a median survival of less than 12 months. Recognizing symptoms early and pursuing prompt diagnostic evaluation can significantly improve outcomes.

Key benefits of early detection include:

• Higher resectability: Complete surgical removal is the primary curative treatment.
• Reduced morbidity: Avoiding complications from hormone excess or tumor invasion.
• Better response to adjuvant therapy: Mitotane and chemotherapy are more effective in early-stage disease.

Diagnostic Approach: From Symptoms to Genetic Testing

When ACC is suspected, a comprehensive evaluation is necessary. This includes:

1. Biochemical testing: Measurement of serum cortisol, ACTH, aldosterone, renin, DHEA-S, and androgens to detect hormonal excess.
2. Imaging: CT or MRI of the abdomen to characterize the adrenal mass and assess local invasion or metastasis.
3. Biopsy: Percutaneous biopsy is generally avoided due to risk of tumor seeding; diagnosis is often confirmed post-surgery.
4. Genetic testing: For patients with features suggestive of hereditary syndromes, germline testing using Next-Generation Sequencing (NGS) or Whole Exome Sequencing (WES) is recommended.

At DNA Labs India, an ISO 9001 certified laboratory, we offer comprehensive genetic panels for hereditary cancer syndromes, including Li-Fraumeni (TP53), Beckwith-Wiedemann, and multiple endocrine neoplasia type 1 (MEN1). These tests utilize advanced NGS technology to identify pathogenic variants that inform both treatment and family screening.

Genetic Testing and Hereditary Syndromes

Approximately 5–10% of ACC cases are associated with inherited syndromes. Identifying these genetic predispositions is crucial for personalized management and surveillance of at-risk family members. Key syndromes include:

• Li-Fraumeni Syndrome (TP53 mutations): Increases risk of ACC, breast cancer, sarcomas, and brain tumors.
• Beckwith-Wiedemann Syndrome: Overgrowth syndrome with increased risk of embryonal tumors, including ACC.
• Multiple Endocrine Neoplasia Type 1 (MEN1): Predisposes to endocrine tumors, including adrenal adenomas and rarely ACC.
• Lynch Syndrome (MLH1, MSH2, etc.): Associated with adrenal cortical tumors in some cases.

Genetic testing is recommended for individuals with ACC diagnosed before age 45, those with bilateral or multifocal tumors, or those with a family history of related cancers. Testing can guide surgical decisions, surveillance protocols, and targeted therapies.

Proactive Health Management

While some risk factors like genetics cannot be modified, adopting a healthy lifestyle and maintaining regular medical checkups can aid in early detection and overall well-being.

• Balanced diet and exercise: Helps manage blood pressure, weight, and hormonal balance.
• Routine health assessments: Regular blood pressure monitoring and physical exams can uncover subtle signs.
• Genetic counseling: For individuals with a family history of endocrine cancers, genetic counseling and testing can provide actionable insights.

When to Consult a Specialist

If you experience persistent symptoms such as unexplained weight gain, muscle weakness, hypertension, or skin changes, especially if they cluster together, consult a physician promptly. Early referral to an endocrinologist or oncologist can expedite diagnosis and treatment.